Two year old Jude David from Hamlyn Terrace is one of 30 children across Australia whose future will be brighter with Cystic Fibrosis drug ‘Kalydeco’ made available to children under the age of six through the Pharmaceutical Benefits Scheme (PBS).
Cystic Fibrosis Australia (CFA) welcomed the announcement from the Health Minister, Greg Hunt, of PBS listing of the life changing drug for children between the ages of 2 and 5 years with CF who have a gating mutation.
CFA says the drug is “the most important development in the treatment of the disease since the discovery of the cystic fibrosis gene in 1989” and works by ‘turning off’ the genetic defect that causes Cystic Fibrosis.
Emma met Caron and Jude and was moved by their story. As a Pharmacist, Emma knows and respects the PBS listing process, its independence and the strict evidence requirements necessary, but saw this as an example where patients and carers voice has been heard.
It's good news that the Government worked with Vertex Pharmaceuticals, which developed Kalydeco.
Access to this drug would improve quality of life and life expectancy for Jude, and the other young people living with this particular condition.